Abstract Details

Title Relevance of Fluorodopa PET Scan in Dopamine Responsive Dystonia and Juvenile Parkinsonism: A Systematic Review

Topic Movement Disorders

Presentation(s) P8 - Poster Session 8 (5:30 PM-6:30 PM)

Poster/Presentation
Number 3-007

Objective

We focused our attention on the FD PET scan mainly because, even though it is not a very common test to perform, it is more available than genetic testing in developing countries. In addition, this test allows us to have a quick, sensitive, specific marker for a disease that prompts treatment and may go undiagnosed for a significant amount of time if there is no test to confirm the correct diagnosis. Finally, it creates a reliable and measurable finding to compare as the diseases progress.

This systematic review aims to gather information about the differentiation of these two diseases in the setting of a young patient with parkinsonian symptoms and its use in the clinical setting.

Background

Dopamine Responsive Dystonia (DRD) and Juvenile Parkinsonism (JP) are two diseases commonly presenting with parkinsonian symptoms in young patients. Current clinical guidelines offer a diagnostic approach based on molecular analysis.

Design/Methods We performed a systematic literature review in English using the preferred reporting items for systematic reviews and meta-analyses (PRISMA) and meta-analysis of observational studies in epidemiology (MOOSE) protocols. We only used human clinical trials about dopamine responsive dystonia and juvenile parkinsonism patients in which a fluorodopa (FD) positron emission tomography (PET) scan was performed to identify its use in these diseases.

Results We included six studies that fulfilled our criteria. We found a clear pattern of decreased uptake in the putamen and caudate nucleus in JP cases. At the same time, the results in DRD were comparable to normal subjects, with only a slightly decreased marker uptake in the previously mentioned regions by the FD PET scan.

Conclusions We found a distinctive pattern for each of these diseases. Identifying these findings with FD PET scans can shorten the delay in making a definitive diagnosis when genetic testing is unavailable, a common scenario in developing countries.

Authors/Disclosures
Juan Moncayo, MD (Texas Tech University Health Sciences Center) PRESENTER	Dr. Moncayo has nothing to disclose.
Maite Vargas	No disclosure on file
Juan Fernando Ortiz, MD (Spectrum Health /Michigan State University)	Dr. Ortiz has nothing to disclose.
Pablo Granda (Hospital Carlos Andrade Marin)	Mr. Granda has nothing to disclose.
Alex S. Aguirre, MD	Mr. Aguirre has nothing to disclose.
Pamela A. Davila-siliezar, MD (Texas Tech University)	Dr. Davila-siliezar has nothing to disclose.
Santiago Rivadeneira Yugsi	No disclosure on file
Jennifer Argudo	Jennifer Argudo has nothing to disclose.
Willians Tambo	No disclosure on file
Gabriela M. Garofalo, MD	Dr. Garofalo has nothing to disclose.
Christian John Capirig (University of Hawaii Internal Medicine Residency Program)	Christian John Capirig has nothing to disclose.
Paula German	No disclosure on file
Luis G. Rueda Carrillo, MD (Wellstar MCG Health)	Dr. Rueda Carrillo has nothing to disclose.

��ɫ��

��ɫ��